Literature DB >> 28009454

Direct estimation for adaptive treatment length policies: Methods and application to evaluating the effect of delayed PEG insertion.

Xin Lu1, Brent A Johnson2.   

Abstract

Dysphagia is a primary cause of death among patients diagnosed with amyotrophic lateral sclerosis (ALS), and percutaneous endoscopic gastrostomy (PEG) is a procedure to insert a tube into the stomach to assist or replace oral feeding. It is believed that PEG is beneficial and, generally, earlier insertion is preferable to later. However, gathering clinical evidence to support these beliefs on the use and timing of PEG is challenging because controlled clinical trials are not feasible and clinical endpoints are confounded with PEG in observational data. Moreover, the confounders are time-varying and time to PEG insertion may be only partially observed. We show how one can view this problem as an adaptive treatment length policy and propose a new estimator via g-computation. We show that our estimator is consistent and asymptotically normal for the causal estimand and explore its finite sample properties in simulation studies. Finally, using more than 10 years of data from Emory ALS clinic registry, we found no evidence to suggest that earlier PEG reduced 4-year mortality; thus, our results do not support the hypothesis and belief that initiating palliative care earlier extends life, on average. At the same, we cannot be certain that all important confounding variables are collected and observed to ensure our modeling assumptions are correct, so more work is needed to address these important end-of-life questions for ALS patients.
© 2016, The International Biometric Society.

Entities:  

Keywords:  Competing risks; Dynamic regime; Informative censoring; Structural nested models; g-computation

Mesh:

Substances:

Year:  2016        PMID: 28009454      PMCID: PMC5491382          DOI: 10.1111/biom.12639

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group.

Authors:  A Chiò; E Finocchiaro; P Meineri; E Bottacchi; D Schiffer
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.

Authors:  R G Miller; J A Rosenberg; D F Gelinas; H Mitsumoto; D Newman; R Sufit; G D Borasio; W G Bradley; M B Bromberg; B R Brooks; E J Kasarskis; T L Munsat; E A Oppenheimer
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.

Authors:  Brent A Johnson; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2004-06       Impact factor: 2.571

4.  Marginal Mean Models for Dynamic Regimes.

Authors:  S A Murphy; M J van der Laan; J M Robins
Journal:  J Am Stat Assoc       Date:  2001-12-01       Impact factor: 5.033

5.  Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia.

Authors:  Abdus S Wahed; Peter F Thall
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2013-01       Impact factor: 1.864

6.  Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis.

Authors:  L Mazzini; T Corrà; M Zaccala; G Mora; M Del Piano; M Galante
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

7.  Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register.

Authors:  Raeburn B Forbes; Shuna Colville; Robert J Swingler
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011.

Authors:  Kim Traxinger; Crystal Kelly; Brent A Johnson; Robert H Lyles; Jonathan D Glass
Journal:  Neurol Clin Pract       Date:  2013-08

Review 9.  Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R G Miller; C E Jackson; E J Kasarskis; J D England; D Forshew; W Johnston; S Kalra; J S Katz; H Mitsumoto; J Rosenfeld; C Shoesmith; M J Strong; S C Woolley
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

  9 in total
  2 in total

1.  Estimating mean potential outcome under adaptive treatment length strategies in continuous time.

Authors:  Hao Sun; Ashkan Ertefaie; Brent A Johnson
Journal:  Biometrics       Date:  2021-06-04       Impact factor: 1.701

Review 2.  A scoping review of studies using observational data to optimise dynamic treatment regimens.

Authors:  Maarten J IJzerman; Julie A Simpson; Robert K Mahar; Myra B McGuinness; Bibhas Chakraborty; John B Carlin
Journal:  BMC Med Res Methodol       Date:  2021-02-22       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.